bsm-52543R-FITC [Conjugated Primary Antibody]
TCF7L2 Recombinant Antibody, FITC Conjugated
www.biossusa.com
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: TCF7L2

Clonality: Recombinant

Isotype: IgG

Entrez Gene: 6934

Swiss Prot: Q9NQB0

Source: Human TCF7L2 aa 1-100

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine.

Conjugation: FITC

Excitation/ Emission: 494nm/518nm

Size: 100µL

Concentration: Lot Dependent

Applications: WB(WB(1:500-2000))
FCM(FCM(1:50-100))
IF(IHC-P)(IF(IHC-P)(1:50-200))
IF(ICC)(IF(ICC)(1:50-200))

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Tao Zhang. et al. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. INT J BIOL SCI. 2022; 18(11): 45604577Read more>>
VALIDATION IMAGES